Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis

Citation
P. Invernizzi et al., Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis, J HEPATOL, 34(3), 2001, pp. 366-372
Citations number
38
Categorie Soggetti
Gastroenerology and Hepatology","da verificare
Journal title
JOURNAL OF HEPATOLOGY
ISSN journal
01688278 → ACNP
Volume
34
Issue
3
Year of publication
2001
Pages
366 - 372
Database
ISI
SICI code
0168-8278(200103)34:3<366:AANPCA>2.0.ZU;2-#
Abstract
Background/Aims: Antibodies against nuclear pore complexes (NPCs) have been detected in primary biliary cirrhosis (PBC), but their clinical relevance is still unsettled. Methods: We tested sera from 171 consecutive PBC patients and 230 control s ubjects (149 with autoimmune or viral liver diseases, 28 with systemic lupu s erythematosus, and 53 healthy) by immunoblotting for antibodies against p urified human NPCs. Results: Antibodies to NPCs were detected in 27% of the patients with PBC, were highly specific (97%), and were not associated with antimitochondrial antibodies. Their prevalence was higher in symptomatic patients (36 vs. 16% , P < 0.01) and was associated (P < 0.001) with more severe disease, as ass essed by the presence of cirrhosis of its complications (13% prevalence in patients without cirrhosis, 31% in uncomplicated, and 54% in complicated ci rrhosis), or by the application of the Mayo prognostic model (12% in the lo west, 21% in the median, 47% in the highest score tertile), Positive patien ts had higher levels of serum bilirubin (2.2 +/- 3.7 vs. 1.0 +/- 1.1 mg/dl, P < 0.01) and more marked inflammatory infiltrates on liver biopsy (P < 0. 05). Conclusions: Autoantibodies to NPCs are more prevalent in PBC patients than in controls and are strongly associated with more active and severe diseas e. (C) 2001 European Association for the Study of the Liver. Published by Else vier Science B.V, All rights reserved.